Philippines Neurodegeneration Biotech Companies

📖 Wiki Page

company1991 wordssynced 2026-04-02

Executive Summary

flowchart TD companies_philippines_neurodeg["Philippines Neurodegeneration Biotech Companies"] style companies_philippines_neurodeg fill:#4fc3f7,stroke:#333,color:#000 companies_philippine_0["Executive Summary"] companies_philippines_neurodeg -->|"includes"| companies_philippine_0 style companies_philippine_0 fill:#81c784,stroke:#333,color:#000 companies_philippine_1["Pharmaceutical Companies"] companies_philippines_neurodeg -->|"includes"| companies_philippine_1 style companies_philippine_1 fill:#ef5350,stroke:#333,color:#000 companies_philippine_2["United Laboratories Unilab Inc."] companies_philippines_neurodeg -->|"includes"| companies_philippine_2 style companies_philippine_2 fill:#ffd54f,stroke:#333,color:#000 companies_philippine_3["iForte Inc."] companies_philippines_neurodeg -->|"includes"| companies_philippine_3 style companies_philippine_3 fill:#ce93d8,stroke:#333,color:#000 companies_philippine_4["Paxion Pharmaceuticals"] companies_philippines_neurodeg -->|"includes"| companies_philippine_4 style companies_philippine_4 fill:#4fc3f7,stroke:#333,color:#000 companies_philippine_5["Flora Biotech Inc."] companies_philippines_neurodeg -->|"includes"| companies_philippine_5 style companies_philippine_5 fill:#81c784,stroke:#333,color:#000

...

Executive Summary

Mermaid diagram (expand to render)

The Philippines represents an emerging hub for neuroscience research and biotechnology innovation in Southeast Asia, with a growing ecosystem of pharmaceutical companies, biotechnology firms, and academic research institutions actively engaged in neurodegenerative disease research. The country's pharmaceutical sector, valued at approximately $3.5 billion, has seen increased investment in central nervous system (CNS) drug development targeting [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), driven by favorable government policies, expanding clinical trial infrastructure, and strong academic partnerships with international research institutions["@philippines_neuro_2023"].

The Philippine government, through the Department of Science and Technology (DOST), has prioritized biotechnology as a key growth sector, implementing policies that encourage local drug development and reduce dependence on imported pharmaceuticals. This strategic focus has catalyzed the emergence of several domestic pharmaceutical companies with active neuroscience programs, alongside academic-medical centers that conduct cutting-edge research into neurodegenerative disease mechanisms relevant to the Filipino population["@biotech_policy"].

Pharmaceutical Companies

United Laboratories (Unilab Inc.)

Headquarters: Manila, Philippines Website: https://www.unilab.com.ph Founded: 1945 Employees: 5,000+

United Laboratories, commonly known as Unilab, is the largest pharmaceutical company in the Philippines, with a market share exceeding 30% of the domestic pharmaceutical market. Founded in 1945, the company has grown from a local drug distributor to a fully integrated pharmaceutical enterprise with manufacturing, research, and distribution capabilities spanning the archipelago[@pharma_trends].

Unilab's CNS division has developed a robust portfolio of medications for neurological disorders, including antiepileptic drugs, medications for Parkinson's disease management, and treatments for Alzheimer's disease symptoms. The company's research and development division, located in its Laguna manufacturing facility, has established collaborations with international pharmaceutical partners to develop novel therapeutics for neurodegenerative diseases[@unilab].

Research Programs:

Alzheimer's Disease Program: Unilab has partnered with international biotechnology companies to develop acetylcholinesterase inhibitors and NMDA receptor antagonists for Alzheimer's disease treatment. The company conducts bioequivalence studies for generic versions of donepezil, rivastigmine, and memantine[@admet].
Parkinson's Disease Program: Research collaborations with Japanese pharmaceutical companies have enabled development of dopaminergic agents and MAO-B inhibitors for Parkinson's disease management.
Neuroprotection Research: Unilab's R&D division investigates natural product-derived compounds with neuroprotective properties, leveraging the Philippines' rich biodiversity of medicinal plants.

Manufacturing Capabilities:
Unilab operates GMP-certified manufacturing facilities in Laguna and Cavite, producing both oral solid dosage forms and injectables. The company's quality systems comply with FDA Philippines and international regulatory standards.

iForte Inc.

Headquarters: Manila, Philippines Website: https://www.iforte.com.ph

iForte Inc. is a Filipino pharmaceutical company specializing in specialty pharmaceuticals, with particular focus on the central nervous system therapeutic area. The company has established itself as a key player in the Philippine CNS market, providing both locally-manufactured and imported specialty medications[@iforte].

Product Portfolio:

Neurological disorder medications (epilepsy, Parkinson's disease)
Alzheimer's disease symptomatic treatments
Neuropsychiatric medications
Specialty injectables for hospital use

Strategic Partnerships:
iForte has entered into licensing agreements with European and Japanese pharmaceutical companies to distribute innovative CNS medications in the Philippines. The company serves as a critical link between international pharmaceutical innovation and Filipino patients requiring specialized neurological care.